Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

Condition:   Skin Neoplasm
Interventions:   Drug: Pembrolizumab;   Drug: Cetuximab
Sponsors:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2x91KxI